Akari Therapeutics ADR
(AKTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,177 | 1,310 | 3,845 | N/A | 7,181 |
| Other current assets | 899 | 1,462 | 496 | 0 | 817 |
| TOTAL | $5,076 | $2,772 | $4,341 | $N/A | $7,997 |
| Non-Current Assets | |||||
| Intangibles | 0 | 0 | 14 | 0 | 16 |
| TOTAL | $N/A | $N/A | $14 | $N/A | $16 |
| Total Assets | $5,076 | $2,772 | $4,355 | $N/A | $8,013 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,686 | 3,208 | 1,671 | 0 | 1,031 |
| Accrued Expenses | 1,685 | 1,530 | 1,566 | N/A | 2,402 |
| Other current liabilities | 1,408 | 1,587 | 1,347 | N/A | 1,705 |
| TOTAL | $8,779 | $6,325 | $4,584 | $N/A | $5,137 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 94 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $94 |
| Total Liabilities | $8,779 | $6,325 | $4,584 | $N/A | $5,232 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 11,953 | 7,924 | N/A | N/A | N/A |
| Common Shares | 2,430 | 1,598 | 1,324 | N/A | 1,012 |
| Retained earnings | -240,585 | -233,027 | -227,461 | N/A | -220,452 |
| Other shareholders' equity | 51,445 | 51,433 | 51,154 | 0 | 51,368 |
| TOTAL | $-3,703 | $-3,553 | $-229 | $N/A | $2,782 |
| Total Liabilities And Equity | $5,076 | $2,772 | $4,355 | $0 | $8,013 |